Multiple sclerosis progression: time for a new mechanism-driven framework

T Kuhlmann, M Moccia, T Coetzee, JA Cohen… - The Lancet …, 2023‏ - thelancet.com
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—
relapsing-remitting, secondary progressive, and primary progressive—for patient care …

Recommendations for cognitive screening and management in multiple sclerosis care

R Kalb, M Beier, RHB Benedict… - Multiple Sclerosis …, 2018‏ - journals.sagepub.com
Purpose: To promote understanding of cognitive impairment in multiple sclerosis (MS),
recommend optimal screening, monitoring, and treatment strategies, and address barriers to …

Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes

L Ruano, E Portaccio, B Goretti… - Multiple Sclerosis …, 2017‏ - journals.sagepub.com
Background: There is limited and inconsistent information on the clinical determinants of
cognitive impairment (CI) in multiple sclerosis (MS). Objective: The aim of this study was to …

Multiple sclerosis and cognition: synaptic failure and network dysfunction

M Di Filippo, E Portaccio, A Mancini… - Nature Reviews …, 2018‏ - nature.com
Cognitive impairment is increasingly recognized to be a core feature of multiple sclerosis
(MS), with important implications for the everyday life of individuals with MS and for disease …

Comprehensive approach to management of multiple sclerosis: addressing invisible symptoms—a narrative review

L Lakin, BE Davis, CC Binns, KM Currie… - Neurology and therapy, 2021‏ - Springer
Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous
system, leading to neurodegeneration and manifesting as a variety of symptoms. These can …

[HTML][HTML] Cognitive impairment in multiple sclerosis: an update on assessment and management

E Portaccio, MP Amato - NeuroSci, 2022‏ - mdpi.com
Cognitive impairment (CI) is a core feature of multiple sclerosis (MS) and affects up to 65%
of patients in every phase of the disease, having a deep impact on all aspects of patients' …

“No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosis

G Giovannoni, D Tomic, JR Bright… - Multiple Sclerosis …, 2017‏ - journals.sagepub.com
Using combined endpoints to define no evident disease activity (NEDA) is becoming
increasingly common when setting targets for treatment outcomes in multiple sclerosis (MS) …

The prevalence of cognitive impairment in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis

W Wu, H Francis, A Lucien, TA Wheeler… - Neuropsychology …, 2024‏ - Springer
It is increasingly recognized that cognitive symptoms are a common sequelae of relapsing-
remitting multiple sclerosis and are associated with adverse functional consequences …

Cognitive dysfunction in the early stages of multiple sclerosis—how much and how important?

M Oset, M Stasiolek, M Matysiak - Current neurology and neuroscience …, 2020‏ - Springer
Abstract Purpose of Review Multiple sclerosis (MS) is a demyelinating disease of the central
nervous system that mainly affects young adults and that is one of the leading causes of …

Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study

M Pitteri, C Romualdi, R Magliozzi… - Multiple Sclerosis …, 2017‏ - journals.sagepub.com
Background: Multiple sclerosis (MS) is a chronic immune-mediated disease of the central
nervous system (CNS). Although cognitive impairment (CI) affects a large proportion of MS …